Benzinga - by Avi Kapoor, Benzinga Staff Writer.
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Medtronic (NYSE: MDT). "I like what they’re doing in AI. You’ve got a good one with a good yield," he noted.
On March 27, the FDA approved Medtronic’s Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
Riley Exploration Permian, Inc. (NYSE: REPX) is actually a very cheap stock, and it has got a good yield. "I don’t understand why it’s here, and I think you should buy it," he added.
On April 4, Riley Permian announced pricing of public offering of $18.9 million common stock at $27.00 per share.
The "Mad Money" host recommended buying WESCO International, Inc. (NYSE: WCC).
On April 1, Wesco International said it has completed the sale of its Wesco Integrated Supply business to Vallen Distribution, Inc for a purchase price of $350 million.
When asked about Cleveland-Cliffs Inc. (NYSE: CLF), he said, "I would buy that stock under 20, that’s my level."
On April 9, Wolfe Research downgraded Cleveland-Cliffs from Peer Perform to Underperform.
Price Action:
- Medtronic shares gained 1.1% to settle at $83.80 on Tuesday.
- Riley Exploration Permian shares fell 1.4% to close at $29.20 during Tuesday’s session.
- Shares of Wesco gained 0.1% to close at $172.78 on Tuesday.
- Cleveland-Cliffs shares fell 2.3% to settle at $21.91 on Tuesday.
Image: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.